[go: up one dir, main page]

FI935431A7 - Kinazolinderivat - Google Patents

Kinazolinderivat Download PDF

Info

Publication number
FI935431A7
FI935431A7 FI935431A FI935431A FI935431A7 FI 935431 A7 FI935431 A7 FI 935431A7 FI 935431 A FI935431 A FI 935431A FI 935431 A FI935431 A FI 935431A FI 935431 A7 FI935431 A7 FI 935431A7
Authority
FI
Finland
Prior art keywords
kianzoline
derivatives
kianzoline derivatives
Prior art date
Application number
FI935431A
Other languages
English (en)
Finnish (fi)
Other versions
FI935431A0 (fi
Inventor
Andrew John Barker
Dearg Sutherland Brown
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929225765A external-priority patent/GB9225765D0/en
Priority claimed from GB939310248A external-priority patent/GB9310248D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of FI935431A0 publication Critical patent/FI935431A0/fi
Publication of FI935431A7 publication Critical patent/FI935431A7/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
FI935431A 1992-12-10 1993-12-03 Kinazolinderivat FI935431A7 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929225765A GB9225765D0 (en) 1992-12-10 1992-12-10 Quinazoline derivatives
GB939310248A GB9310248D0 (en) 1993-05-18 1993-05-18 Quinazoline derivatives

Publications (2)

Publication Number Publication Date
FI935431A0 FI935431A0 (fi) 1993-12-03
FI935431A7 true FI935431A7 (sv) 1994-06-11

Family

ID=26302132

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935431A FI935431A7 (sv) 1992-12-10 1993-12-03 Kinazolinderivat

Country Status (19)

Country Link
US (1) US5580870A (sv)
EP (1) EP0602851B1 (sv)
JP (1) JP3330706B2 (sv)
KR (1) KR940014355A (sv)
CN (1) CN1094043A (sv)
AT (1) ATE143956T1 (sv)
AU (1) AU664496B2 (sv)
CA (1) CA2103383C (sv)
CZ (1) CZ283612B6 (sv)
DE (1) DE69305310T2 (sv)
DK (1) DK0602851T3 (sv)
ES (1) ES2093367T3 (sv)
FI (1) FI935431A7 (sv)
GB (1) GB9323290D0 (sv)
GR (1) GR3021326T3 (sv)
HU (1) HUT65622A (sv)
IL (1) IL107678A (sv)
NO (1) NO304487B1 (sv)
NZ (1) NZ250218A (sv)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1995023141A1 (en) * 1994-02-23 1995-08-31 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
DK0682027T3 (da) * 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
TW321649B (sv) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5932574A (en) * 1995-04-27 1999-08-03 Zeneca Limited Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
AU719434B2 (en) 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
DE69710712T3 (de) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
WO1998056376A1 (en) * 1997-06-13 1998-12-17 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
US6323209B1 (en) 1997-11-06 2001-11-27 American Cyanamid Company Method of treating or inhibiting colonic polyps
US6756367B2 (en) 1998-02-03 2004-06-29 Novartis Ag Benzo-oxadiazoles, -thiadiazoles and -1,4-diazines, pharmaceutical compositions containing them and a process for preparing them
GB9802251D0 (en) * 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
PL196940B1 (pl) * 1998-04-29 2008-02-29 Osi Pharmaceuticals Bezwodna postać i monohydrat mesylanu N-(3-etynylofenylo)-6,7-bis (2-metoksyetoksy)-4-chinazolinaminy
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
TR200003513T2 (tr) 1998-06-02 2001-06-21 Osi Pharmaceuticals, Inc. Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
US6384223B1 (en) 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
HU230728B1 (hu) 1998-09-29 2017-12-28 Wyeth Holdings Llc Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
MXPA01008182A (es) * 1999-02-10 2003-08-20 Astrazeneca Ab Derivados de quinazolina como inhibidores de angiotensina.
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
EP1676845B1 (en) 1999-11-05 2008-06-11 AstraZeneca AB New quinazoline derivatives
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
DK1274692T3 (da) 2000-04-07 2006-10-30 Astrazeneca Ab Quinazolinforbindelser
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CA2419301C (en) 2000-08-21 2009-12-08 Astrazeneca Ab Quinazoline derivatives
AU2001292137A1 (en) * 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives
AU2001292138A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US20040063733A1 (en) * 2000-10-25 2004-04-01 Lambert Christine Marie Paul Quinazoline derivatives
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
DK1370553T3 (da) * 2001-03-23 2006-09-11 Bayer Corp Rho-kinase-inhibitorer
AR035792A1 (es) * 2001-03-23 2004-07-14 Bayer Corp Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
WO2002085895A1 (en) 2001-04-19 2002-10-31 Astrazeneca Ab Quinazoline derivatives
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
KR100397792B1 (ko) 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
JP2005529062A (ja) * 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１及びａ３受容体に特異的な化合物とその使用
CN101973998A (zh) * 2001-12-20 2011-02-16 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物
CN1620294A (zh) 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
EP1471910A2 (en) * 2002-01-17 2004-11-03 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
US7268230B2 (en) 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP2006502995A (ja) * 2002-07-19 2006-01-26 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４阻害剤としての６−アミノ−１ｈ−インダゾール及び４−アミノベンゾフラン化合物
US20050239852A1 (en) 2002-08-02 2005-10-27 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US7560558B2 (en) 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
ES2300619T3 (es) * 2002-11-04 2008-06-16 Astrazeneca Ab Derivados de quinolina como inhibidores de src tirosina quinasa.
TW200418480A (en) * 2002-12-13 2004-10-01 Neurogen Corp 2-substituted quinazolin-4-ylamine analogues
AU2003285614B2 (en) 2002-12-20 2009-05-14 Pfizer Products, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
GB0302876D0 (en) * 2003-02-07 2003-03-12 Novartis Ag Organic compounds
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
GB0318422D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
JP4036885B2 (ja) 2003-09-19 2008-01-23 アストラゼネカ アクチボラグ キナゾリン誘導体
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
PL1684750T3 (pl) 2003-10-23 2010-10-29 Ab Science 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
JP4503022B2 (ja) 2003-12-23 2010-07-14 ファイザー・インク 新規キノリン誘導体
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
US7626030B2 (en) 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
KR20070026390A (ko) * 2004-01-23 2007-03-08 암젠 인코포레이션 화합물 및 사용방법
US7687502B2 (en) * 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
AP2204A (en) 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
JP2008521900A (ja) * 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
US7947676B2 (en) 2004-12-14 2011-05-24 Astrazeneca Ab Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
PL1854789T3 (pl) 2005-02-23 2014-03-31 Shionogi & Co Pochodna chinazoliny mająca aktywność hamowania kinazy tyrozynowej
EP1856095B1 (en) 2005-02-26 2011-08-24 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
ES2319462T3 (es) * 2005-03-28 2009-05-07 Bristol-Myers Squibb Company Inhibidores competitivos de atp cinasas.
MX2007012392A (es) 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
WO2007034144A1 (en) 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
US20070231298A1 (en) * 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
CN101100466B (zh) 2006-07-05 2013-12-25 天津和美生物技术有限公司 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
US8246966B2 (en) 2006-08-07 2012-08-21 University Of Georgia Research Foundation, Inc. Trypanosome microsome system and uses thereof
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2088863A2 (en) 2006-11-22 2009-08-19 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
CN101367794B (zh) * 2007-07-20 2013-07-10 上海恒瑞医药有限公司 喹唑啉类衍生物的制备方法及其在医药上的应用
CA2703257C (en) * 2007-10-29 2013-02-19 Amgen Inc. Benzomorpholine derivatives and methods of use
EP2220054A2 (en) 2007-10-29 2010-08-25 Natco Pharma Limited Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
NZ586946A (en) 2008-01-18 2012-06-29 Natco Pharma Ltd 6,7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
DE102008009609A1 (de) 2008-02-18 2009-08-20 Freie Universität Berlin Substituierte 4-(Indol-3-yl)chinazoline und deren Verwendung und Herstellung
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
AU2010285740C1 (en) 2009-08-19 2016-03-17 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
SG178592A1 (en) 2009-09-03 2012-04-27 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
ES2543151T3 (es) 2010-10-20 2015-08-17 Pfizer Inc Derivados de 2-piridina como moduladores del receptor Smoothened
CN102485735B (zh) * 2010-12-02 2014-09-24 东莞南方医大代谢医学研发有限公司 6-果糖氨-4-芳胺基喹唑啉衍生物及其用途
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2847540C (en) 2011-09-22 2016-05-17 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
ES2889757T3 (es) * 2012-09-06 2022-01-13 Plexxikon Inc Compuestos y procedimientos para la modulación de quinasas e indicaciones para estos
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
CA2900680C (en) 2013-02-20 2021-08-10 Kala Pharmaceuticals, Inc. Quinoline and quinazoline compounds and uses thereof for treating and/or preventing diseases
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9654758B2 (en) * 2013-04-26 2017-05-16 Microsoft Technology Licensing, Llc Synchronizing external data to video playback
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN104163815B (zh) * 2013-05-17 2017-11-28 温州医学院 含吲哚的喹唑啉类化合物及其在治疗egfr依赖性肿瘤疾病中的用途
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
KR20160149256A (ko) 2014-04-30 2016-12-27 화이자 인코포레이티드 시클로알킬-결합된 디헤테로사이클 유도체
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
JP6659554B2 (ja) 2014-08-28 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 高純度キノリン誘導体およびその製造方法
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US10450299B2 (en) 2015-03-25 2019-10-22 Centre National De La Recherche Scientifique (Cnrs) Substituted quinazoline derivatives as DNA methyltransferase inhibitors
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US11040984B2 (en) * 2016-12-30 2021-06-22 Medshine Discovery Inc. Quinazoline compound for EGFR inhibition
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
KR20200013644A (ko) 2017-05-16 2020-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포 암종의 치료
KR20240017986A (ko) * 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
FR3080620B1 (fr) * 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
EP4304727A1 (en) * 2021-03-10 2024-01-17 Blueprint Medicines Corporation Egfr inhibitors
WO2024059169A1 (en) * 2022-09-14 2024-03-21 Blueprint Medicines Corporation Egfr inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470182A (en) 1967-02-09 1969-09-30 Sandoz Ag 4-amino-substituted quinazolines
JPH078851B2 (ja) 1985-07-29 1995-02-01 鐘淵化学工業株式会社 ３−フエニルチオメチルスチレン誘導体
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
DE3874257T2 (de) 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
AU632992B2 (en) 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
DE3917982A1 (de) 1989-06-02 1990-12-06 Behringwerke Ag Verwendung von xylanpolyhydrogensulfaten zur therapie von zellproliferations-bedingten erkrankungen
DE9290018U1 (de) * 1991-02-20 1993-10-14 Pfizer Inc., New York, N.Y. 2,4-Diaminochinazolin-Derivate zur Verbesserung der Antitumor-Aktivität
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
JP3330706B2 (ja) 2002-09-30
KR940014355A (ko) 1994-07-18
DK0602851T3 (da) 1997-03-24
CA2103383C (en) 2005-01-25
EP0602851B1 (en) 1996-10-09
EP0602851A1 (en) 1994-06-22
CN1094043A (zh) 1994-10-26
NZ250218A (en) 1996-06-25
GB9323290D0 (en) 1994-01-05
IL107678A (en) 1999-03-12
NO934504L (no) 1994-06-13
DE69305310T2 (de) 1997-02-13
AU664496B2 (en) 1995-11-16
NO934504D0 (no) 1993-12-09
AU5072893A (en) 1994-06-23
DE69305310D1 (de) 1996-11-14
ES2093367T3 (es) 1996-12-16
FI935431A0 (fi) 1993-12-03
CZ265193A3 (en) 1994-06-15
HUT65622A (en) 1994-07-28
JPH06336481A (ja) 1994-12-06
CZ283612B6 (cs) 1998-05-13
CA2103383A1 (en) 1994-06-11
IL107678A0 (en) 1994-02-27
US5580870A (en) 1996-12-03
ATE143956T1 (de) 1996-10-15
GR3021326T3 (en) 1997-01-31
NO304487B1 (no) 1998-12-28

Similar Documents

Publication Publication Date Title
FI930208L (fi) Kinazolinderivat
FI935431A7 (sv) Kinazolinderivat
FI980341A7 (sv) 2-oxindolderivat
ATA75293A (de) Indolderivate
FI933037A7 (fi) Tiazolylvinylfenylderivat
FI941423A7 (sv) 17beta-substituerade 4-aza-5alfa-androstan-3-onderivat
DE69208877D1 (de) Chinuclidinderivate
FI924160A7 (fi) Benzanilidderivat
FI935726A7 (sv) Azanorbornanderivat
FI924159L (fi) Benzanilidderivat
NO922182D0 (no) Krystallinske oksatiolan-derivater
FI943976A7 (sv) 5-arylindolderivat
DE69330497D1 (de) Chinazolin-derivate
FI925763A0 (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
FI923726L (fi) Sulfaterade glykosaminoglykanoidderivat
FI20010214A7 (sv) Acylaminoindolderivat
DE59308714D1 (de) Cyclobutan-benzol-derivate
FI20002460L (sv) 4-difenylmetylpiperidinderivat
FI942444A7 (sv) Tetrahydropyranderivat
FI943885L (sv) Penamderivat
FI935243L (fi) Pyridonkarboxylsyraderivat
FI944044L (sv) Fenylalkanolaminderivat
FI920394A7 (sv) 3-kinuklidinderivat
NO952288D0 (no) Benzazepinon-derivater
DE69313890D1 (de) 5-Aminoflavon-Derivate

Legal Events

Date Code Title Description
FD Application lapsed